These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. TGF-β1 gene polymorphism in renal transplant patients with and without gingival overgrowth. Kozak M; Kurzawski M; Wajda A; Lapczuk J; Lipski M; Dziewanowski K; Drozdzik M Oral Dis; 2011 May; 17(4):414-9. PubMed ID: 21306480 [TBL] [Abstract][Full Text] [Related]
43. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation. Glowacki F; Lionet A; Buob D; Labalette M; Allorge D; Provôt F; Hazzan M; Noël C; Broly F; Cauffiez C Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300 [TBL] [Abstract][Full Text] [Related]
44. Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism. Fanta S; Jönsson S; Karlsson MO; Niemi M; Holmberg C; Hoppu K; Backman JT J Clin Pharmacol; 2010 May; 50(5):581-97. PubMed ID: 20107201 [TBL] [Abstract][Full Text] [Related]
45. Multidrug-resistance 1 gene single-nucleotide polymorphisms do not influence long-term graft survival after kidney transplantation. Saracino A; Muscaridola N; Cifarelli RA; Stallone G; Grandaliano G; Santarsia G Transplant Proc; 2014 Sep; 46(7):2214-9. PubMed ID: 25242754 [TBL] [Abstract][Full Text] [Related]
46. A pharmacogenetic study of ABCB1 polymorphisms and cyclosporine treatment response in patients with psoriasis in the Greek population. Vasilopoulos Y; Sarri C; Zafiriou E; Patsatsi A; Stamatis C; Ntoumou E; Fassos I; Tsalta A; Karra A; Roussaki-Schulze A; Sotiriadis D; Mamuris Z; Sarafidou T Pharmacogenomics J; 2014 Dec; 14(6):523-5. PubMed ID: 24889923 [TBL] [Abstract][Full Text] [Related]
47. CYP and SXR gene polymorphisms influence in opposite ways acute rejection rate in pediatric patients with renal transplant. Turolo S; Edefonti A; Ghio L; Testa S; Morello W; Montini G BMC Pediatr; 2020 May; 20(1):246. PubMed ID: 32450827 [TBL] [Abstract][Full Text] [Related]
48. Pharmacogenetic Study of the Impact of Chernov A; Kilina D; Smirnova T; Galimova E Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432633 [TBL] [Abstract][Full Text] [Related]
49. The effect of Shao S; Hu L; Han Z; Hou K; Fang H; Zhang G; Feng Y; Huang L Transl Androl Urol; 2020 Apr; 9(2):673-683. PubMed ID: 32420174 [TBL] [Abstract][Full Text] [Related]
50. Pharmacogenomics of Old and New Immunosuppressive Drugs for Precision Medicine in Kidney Transplantation. Turolo S; Edefonti A; Syren ML; Montini G J Clin Med; 2023 Jul; 12(13):. PubMed ID: 37445489 [TBL] [Abstract][Full Text] [Related]
51. Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients. Job KM; Roberts JK; Enioutina EY; Illamola SM; Kumar SS; Rashid J; Ward RM; Fukuda T; Sherbotie J; Sherwin CM Expert Opin Drug Metab Toxicol; 2021 Jul; 17(7):747-765. PubMed ID: 34121566 [No Abstract] [Full Text] [Related]
52. Effect of MDR1 gene polymorphisms on mortality in paraquat intoxicated patients. Kim HJ; Kim HK; Kwon JT; Lee SH; El Park S; Gil HW; Song HY; Hong SY Sci Rep; 2016 Aug; 6():31765. PubMed ID: 27545861 [TBL] [Abstract][Full Text] [Related]
54. Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study. Llaudó I; Colom H; Giménez-Bonafé P; Torras J; Caldés A; Sarrias M; Cruzado JM; Oppenheimer F; Sánchez-Plumed J; Gentil MÁ; Ekberg H; Grinyó JM; Lloberas N Transpl Int; 2013 Feb; 26(2):177-86. PubMed ID: 23216707 [TBL] [Abstract][Full Text] [Related]
55. The potential of steroids and xenobiotic receptor polymorphisms in forecasting cyclosporine pharmacokinetic variability in young kidney transplant recipients. Ferraresso M; Turolo S; Belinghieri M; Tirelli AS; Grillo P; Groppali E; Edefonti A; Ghio L Pediatr Transplant; 2012 Sep; 16(6):658-63. PubMed ID: 22765024 [TBL] [Abstract][Full Text] [Related]
56. Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients. Zhang Y; Li JL; Fu Q; Wang XD; Liu LS; Wang CX; Xie W; Chen ZJ; Shu WY; Huang M Acta Pharmacol Sin; 2013 Apr; 34(4):555-60. PubMed ID: 23503472 [TBL] [Abstract][Full Text] [Related]
57. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Anglicheau D; Thervet E; Etienne I; Hurault De Ligny B; Le Meur Y; Touchard G; Büchler M; Laurent-Puig P; Tregouet D; Beaune P; Daly A; Legendre C; Marquet P Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055 [TBL] [Abstract][Full Text] [Related]
58. The Effect of ABCB1 C3435T Polymorphism on Cyclosporine Dose Requirements in Kidney Transplant Recipients: A Meta-Analysis. Lee J; Wang R; Yang Y; Lu X; Zhang X; Wang L; Lou Y Basic Clin Pharmacol Toxicol; 2015 Aug; 117(2):117-25. PubMed ID: 25536375 [TBL] [Abstract][Full Text] [Related]
59. Long-term effects of ABCB1 and SXR SNPs on the systemic exposure to cyclosporine in pediatric kidney transplant patients. Ferraresso M; Belingheri M; Turolo S; Ghio L; Tirelli AS; Grillo P; Lepore M; Edefonti A Pharmacogenomics; 2013 Oct; 14(13):1605-13. PubMed ID: 24088131 [TBL] [Abstract][Full Text] [Related]